ACM
KDNY

Aquilo Capital Management’s Chinook Therapeutics, Inc. Common Stock KDNY Stock Holding History

Aquilo Capital Management’s Portfolio KDNY Stock Details KDNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-421,056
Closed -$15.5M – 15
2018
Q3 		$15.5M Buy
421,056
+19,476
+5% +$625K 6.48% 5
2018
Q2 		$14.1M Buy
+401,580
New +$15.4M 11.59% 4

Other funds holding KDNY

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
FLAM
First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Aquilo Capital Management's KDNY Position: Q4 2018 in Review

Aquilo Capital Management sold out of Chinook Therapeutics, Inc. Common Stock (KDNY) in Q4 2018, closing a stake of 421,056 shares — an estimated $15.5M sold.

Aquilo Capital Management first reported a position in KDNY in Q2 2018 and held it in 2 quarters. The position peaked at $15.5M in Q3 2018. 85 funds tracked by Wall St. Rank hold KDNY as of Q4 2018.

  • Aquilo Capital Management reported no remaining Chinook Therapeutics, Inc. Common Stock position as of Q4 2018 after selling out during the quarter.
  • Aquilo Capital Management sold 421,056 Chinook Therapeutics, Inc. Common Stock shares in Q4 2018, an estimated $15.5M.
  • Aquilo Capital Management first reported a position in Chinook Therapeutics, Inc. Common Stock in Q2 2018 and held it in 2 quarters.
  • Aquilo Capital Management's Chinook Therapeutics, Inc. Common Stock position peaked at $15.5M in Q3 2018.
  • 85 funds tracked by Wall St. Rank held Chinook Therapeutics, Inc. Common Stock as of Q4 2018.

Based on Aquilo Capital Management's 13F filing for Q4 2018, filed 14 Feb 2019.